IMPORTANCE Molecular diagnosis is difficult to achieve in disease groups with a highly heterogeneous genetic background, such as cerebellar ataxia (CA). In many patients, candidate gene sequencing or focused resequencing arrays do not allow investigators to reach a genetic conclusion.
H ereditary cerebellar ataxias (CAs) are clinically and genetically heterogeneous. All transmission modes have been described. The cardinal cerebellar syndrome is frequently part of a complex clinical spectrum with additional neurologic and/or extraneurologic symptoms. 1 The most frequent autosomal recessive (AR) CAs are Friedreich ataxia, caused by GAA repeat expansions in intron 1 of FXN (OMIM 606829), 2 and ataxia-telangiectasia, caused by loss-of-function mutations in ATM (OMIM 607585). 3 Nonclassic clinical pictures have been described for both. 4 ,5 Autosomal dominant (AD) CAs are most often caused by CAG repeat expansions in ATXN1 (OMIM 601556), ATXN2 (OMIM 601517), ATXN3 (OMIM 607047), CACNA1A (OMIM 601011), ATXN7 (OMIM 607640), TBP (OMIM 600075), or ATN1 (OMIM 607462). 6 Overall, mutations in more than 140 genes have been described, involving pathways such as mitochondrial functions, DNA repair, transcription and translation, ciliary structure, and lipid biosynthesis. 1, 7 Sanger sequencing of candidate genes or panel approaches 8 often fails to lead to a diagnosis. 1 We aimed to evaluate the efficacy of exome-capture sequencing followed by targeted analysis of genes broadly linked to CA 9-12 to identify mutations in 319 patients with undiagnosed CA and without an AD transmission history. To our knowledge, this CA cohort is the largest studied.
Methods

Patient Recruitment and Clinical Evaluation
Three hundred nineteen index cases of CA were recruited by the Spastic Paraplegia and Ataxia (SPATAX) network (https://spatax.wordpress.com/) and examined using a standardized form (https://spatax.files.wordpress.com/2013 /09/fichecliniquespatax-eurospa-2011.pdf). The sexes were equally distributed. For the 210 patients with available information, the national origin was mostly France (112 [53.3%]) and continental Europe (39 [18.6%]). We classified the 298 cases with full phenotypic information into the following 6 clinical groups: (1) pure ataxic phenotype (n = 62), (2) additional spastic component (spastic ataxia) (n = 100), (3) complex late-onset clinical picture with extrapyramidal signs (n = 30), (4) metabolic presentation with mitochondrial features (sensorineural hearing loss, ptosis, ophthalmoplegia, optic atrophy, axonal neuropathy, cardiomyopathy, short stature, and/or diabetes type 1) or white matter changes (n = 70), (5) sensory ataxia (n = 19), or (6) a CA with oculomotor apraxia (AOA)-like presentation (n = 17) (Table) . The remaining 21 patients were unclassified. The patients' familial anamneses included no evidence of AD transmission. Recessive inheritance was considered to be plausible based on consanguinity 
Variants Processing
Biallelic (homozygous or compound heterozygous) variants were first sought because of the likelihood of AR inheritance. Very rare (≤0.1% frequency in the aforementioned databases) heterozygous variants were also considered in ADCA genes (eTable 1 in the Supplement and Figure 1 ). The plausibility of genotype-phenotype correlations was evaluated for all flagged variants. Sanger sequencing was performed if (1) the variant read depth was below 10 × , (2) informative family members were available for segregation (other affected members [n = 13] or healthy relatives without biallelic mutations [n = 6]), or (3) it allowed determining the cis-o rtrans-localization of compound heterozygous variants (n = 7). All Sanger resequenced variants and segregation results are reported in eTable 2 in the Supplement.
Results
The 319 included patients had equal sex distribution (160 female [50.2%] and 159 male [49.8%] patients). Mean (SD) age at onset was 27.9 (18.6) years; the age at onset was younger than 25 years for 131 of 298 patients (44.0%) with complete clinical data.
Sequencing
Approximately 8 gigabases of alignable sequence data were generated per sample. On average, 95% of exome capture baits had at least a 10 × depth and 70% at least a 30 × depth. A total of 488 393 single-nucleotide polymorphisms and 69 480 indels were included. We deliberately retained patients with low coverage to avoid distorting the percentage of positive findings.
Variant Analysis
The aforementioned analysis ( Figure 1 ) provided 0 to 4 (AR) or 0 to 2 (AD) candidate genes per patient. We defined the following 4 pathogenicity groups: (1) probable or definitive causative variant(s), including a known or a recurrent variant, 3 or 4 concordant pathogenicity predictions by sorting intolerant from tolerant (SIFT), polymorphism phenotyping 2 (PolyPhen2) HumDiv, LRT, and Mutation Taster and Genomic Evolutionary Rate Profiling (GERP++) score of greater than 3 and plausible genotype-phenotype association, or compatible biomarker values (such as hexaminidase levels); (2) possibly causative variant(s), including most of the above but at least 1 criterion missing, or a slightly discordant phenotype for the gene spectrum; (3) variant(s) of clinically unknown significance (VUS); and (4) no diagnosis, including no variant in a known gene or a variant in known genes without convincing genetics arguments to match the clinical phenotype or the adequate inheritance mode. We obtained very probable or definite diagnoses for 72 patients (22.6%; including 62 with AR and 10 with AD inheritance) (Figure 1 ). We identified possibly causative variants for an additional 19 patients (6.0%; 12 with AR and 7 with AD inheritance). The most frequently encountered recessive mutations were in SPG7 (n = 14), followed by SACS (n=8 ),SETX (n = 7), and SYNE1 (OMIM 608441)(n=6) (Figure 2 ). Dominant mutations were most numerous in CACNA1A (n = 6), followed by PRKCG (OMIM 176980) (n = 3). Possible to definite variants are listed in eTable 2 in the Supplement,witharguments for their classification; VUS are available in eTable 3 in the Supplement.
Diagnostic Yield per Clinical Group
The best diagnositic yields were found for AOA-like presentations with positive biological biomarkers (6 of 17 [35.3%]) and Diagnoses per Gene and Disease Group   SPG7  SACS  SETX  SYNE1  ADCK3  ANO10  CYP7B1  HEXA  KIF1C  PLA2G6  PNPLA6  POLG  RNF216  SPG11  TTPA  ALS2  APTX  ATM  C10orf2  CEP290  CLN5  ERCC5  GBA2  HSD17B4  PMM2  PRKCG  SNX14   CACNAIA  AFG3L2  PRKCG  ITPR1  KCND3  SPTBN2  TTBK2   2  4  6  8 ), whereas patients with AOA show earlier onset. Onset at 24 years of age in this patient was coherent with ANO10 mutations. We classified the diagnosis as possible because the clinical presentation was slightly unusual. Other patients with biallelic loss-of-function ANO10 variants had classic spastic ataxia.
One patient (AFT-76-10) with epilepsy, thus classified in the metabolic group, carried a CACNA1A frameshift (NM _001127222.1:c.2493dupC:p.N832fs). Autosomal recessive inheritance was first assumed because of a consanguineous pedigree, but a dominant history later appeared, with ataxic signs in the daughter of a cousin, for whom no DNA was available for testing.
One patient with spastic ataxia (SAL-399-573) harboured 2 nonsense variants in SYNE1 (NM_182961.3:c.14273T>G: p.L4758X;c.23346G>A:p.W7782X). Pyramidal signs were classically limited in the SYNE1 spectrum, but recent results have established that spasticity is part of the phenotype.
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Reports of Peculiar Phenotypes
We classified a previously reported PDYN variant (NM_001190898.2:c.616C>T:p.R206C 21 )a sV U S .I t sf r equency in the Exome Aggregation Consortium (0.026%, or 16 heterozygous individuals), the lack of an effect on prodynorphin processing to dynorphin A and B, 21 and the discordant phenotype of this French patient (AAR-287-4 with childhoodonset ataxia, intellectual disability, and behavioral abnormalities) relative to the previously reported late-onset spastic ataxia cast its pathogenicity in doubt. We found a possibly causative KCND3 variant (NM _004980.4:c.641A>G:p.K214R) in a patient with an unusual episodic gait disorder. The onset of relapsing limb paraesthesia at 30 years of age first evoked multiple sclerosis. Vertigo and episodic occurrences of gait disorder appeared thereafter without interictal ataxia. Increased reflexes, the Hoffmann sign, unilateral extensor plantar reflexes, and saccadic ocular pursuit were observed. Magnetic resonance imaging showed superior cerebellar vermis atrophy. The unaffected mother carried the variant, suggesting incomplete penetrance. This finding might be in accordance with its prevalence in public databases ( 
Discussion
We used exome-targeted capture sequencing followed by targeted analysis of genes broadly linked to CA to study 319 patients with undiagnosed CA, the largest such cohort to date, to assess the possibility of detecting mutations with this approach and their prevalence. Previously reported cohorts included no more than 76 patients.
9
Our diagnostic yield was 22.6% (72 of 319 patients), with 5.9% (19 of 319) possible additional diagnoses (Figure 1 ). This rate might be lower because our cohort, recruited through a specialized university-based network of reference centers for rare diseases, has undergone extensive screening previously. However, these findings are similar to those of previous reports using targeted gene panels (18% 8 ) or exome sequencing (21%-46% [8] [9] [10] [11] [12] 25 ) and other mendelian diseases (34% diagnoses in heterogeneous patients 26 ; 33% in hereditary spastic paraplegia 27 ). The diagnostic yield was highly variable among clinical subgroups, being the highest for AOA-like phenotypes and spastic ataxias and the lowest for late-onset complex cases. It was also lower in patients with onset after 40 years of age (6.4%), in accordance with other observations. 8, 25 This finding may be explained by less extensive knowledge of genes implicated in late-onset ataxias or by the more frequent involvement of nongenetic causes. In 9 cases, the diagnosis was established during the study but not confirmed. Five patients carried disease-causing repeat expansions, which cannot be detected by short-read techniques owing to the limited read length. These 5 patients included 1 with a heterozygous ATXN7 polyglutamine expansion, 1 with a heterozygous and 1 with a homozygous ATXN3 polyglutamine expansion, and 2 with pathogenic expansions in FXN. In this predominantly AR-assumed population, CAG repeat expansions in ATXN1, ATXN2, ATXN3, CACNA1A, ATXN7, TBP, and ATN1 were sought based only on suggestive clinical elements on examination, as were GAA repeats in FXN. A sixth patient harboured a homozygous 31-kb deletion in ANO10 encompassing exon 12 that was not detected by our approach. Mutations in NDRG1 (OMIM 605262) were reported in another patient during the study process. This gene, mostly implicated in Charcot-Marie-Tooth disease type 4D, was not included in our list. Finally, 2 patients flagged by quality check metrics were diagnosed with APTXlinked and SPG7-linked CA, but low global coverage prohibited from detecting the variants.
Exome-targeted capture sequencing is widely available and has several advantages compared with other sequencing approaches. If targeted gene panel sequencing is a costeffective alternative to focus on many genes in 1 run, it requires an additional design step and redesign as new genes are linked to CA. Conversely, exome capture allows post hoc reanalysis of data as other groups identify mutations in new (CA) genes. For example, 2 patients not included in the claimed diagnosed group carried mutations in CAPN1 28 and 2 others carried mutations in SLC25A46.
29
This approach also allows a broader range of genes to be tested. When AR inheritance is the prime hypothesis, genes with AD-transmitted mutations might be overlooked. Even without a dominant transmission history, AD analysis yielded a significant amount of additional diagnoses ( Figure 1 and Figure 2 ), including 3 in consanguineous pedigrees. Two diagnoses were pathogenic, including a previously reported PRKCG mutation and a CACNA1A frameshift, which is classic for this gene. 30 Possible explanations include the de novo occurrence of the variant, incomplete penetrance, a censor effect owing to premature death, or paternity issues. Autosomal dominant analysis significantly raised the number of VUS because missense heterozygous variations are difficult to interpret. Our results confirm CACNA1A as a prominent gene in CA, which we also confirmed in an independent AD cohort.
31
We often did not have access to DNA from relatives because patients were from an adult neurologic clinic and were enrolled during the course of several years. Access to DNA from relatives would have allowed the detection of de novo variants or confirmation of the localization of heterozygous compound mutations in trans. Whenever possible, sequencing a trio might prove to be more efficacious. In general, next-generation approaches circumvent the issue of gene prioritization based on phenotypic presumptions, with the limitation of the aforementioned expansions. This nonsystematic, time-consuming, classic approach missed the diagnosis in the prescreened patients in the absence of pathognomonic signs. Most genes mutated in our cohort were implicated in only 1 or 2 patients ( Figure 2 ). Furthermore, exome-targeted capture sequencing allows a broader range of genes to be tested, including genes associated with neurologic diseases but not typically with ataxia. We enlarged the clinical spectrum linked to genes for which the phenotype is not primarily CA, such as ERCC5, PLA2G6,orSPG7. Careful examination of clinical records revealed suggestive signs of these syndromes in most cases. However, they were not sufficiently suggestive to have been evoked at first glance. Moreover, mutations in a given gene can lead to divergent phenotypes spread over several clinical groups (≤4 for SYNE1, SETX, and ADCK3). Capturing the exome makes it possible to avoid prior assumptions about the causative gene. 
Research Original Investigation
Efficacy of Exome-Targeted Capture Sequencing to Detect Mutations in Cerebellar Ataxia Genes Spastic paraplegia genes are the most frequent example of phenotype broadening, with mutations in SPG7 and SACS as well as CYP7B1, SPG11, and PLA2G6 ( Figure 2 and eTable 2 in the Supplement). SPG7 mutations were recently recognized to be a major cause of CA 32 ; most patients, however, develop pyramidal signs along with disease progression. In our cohort, 9 of 14 patients with SPG7 mutations had a spastic phenotype (64.3%) and 2 of 14 had pyramidal signs, although they were classified as metabolic. Six of 8 patients with SACS mutations (75.0%) presented with spastic ataxia, and 1 presented with pyramidal signs and demyelinating neuropathy. One patient harbouring possibly causative variants had a less classic phenotype of peripheral neuropathy, epilepsy, and myoclonus. Testing for a trait biomarker, such as an alteration of mitochondrial network morphology in fibroblasts, 33 might help to reach a definite conclusion.
Convincing genetic data, however, usually correlated with a characteristic phenotype. In some cases, the clinical features reinforced the genetic diagnostic presumption. We did not use the clinicogenetic correlation as an exclusion criterion when the variant was genetically convincing, as suggested by others, 9,34 although we classified patients with discordant clinical signs as possibly diagnosed, except for 1 CACNA1A frameshift. Instead, we used clinicogenetic correlation to strenghten evidence of pathogenicity. Genotypephenotype correlations are highly challenged by nextgeneration sequencing, 7 but clinical presentation, including neuroimaging findings, such as the degree of cerebellar atrophy or abnormal basal ganglia signal, should remain a prominent criterion in deciphering the pathogenicity of a given variant for a given patient.
35
When available, trait biomarkers also aid the establishment of the pathogenicity of variants, as shown by the wellknown example of elevated α-fetoprotein levels in ataxiatelangiectasia linked to ATM mutations. Oxysterol levels in patients harbouring CYP7B1 mutations are usually elevated, as in 1 patient carrying a homozygous nonsense variant (NM _004820.4:c.524G>A:p.W175X). Individuals with mutations in HEXA have low levels of hexaminidase A, as in 1 patient with an AOA-like presentation and a homozygous missense mutation (NM_000520.5:c.1511G>A:p.R504H) who was considered to be diagnosed despite discordant in silico pathogenicity estimates. Another patient with a spastic phenotype carried 2 missense variants (NM_000520.5:c.739C>T:p.R247W; c.1033G>A:p.G345S) for which pathogenicity could not be confirmed by hexaminidase dosage and that we thus labeled possibly pathogenic. TTPA mutations are usually accompanied by vitamin E deficiency. This was confirmed in one patient with a homozygous frameshift (NM_000370.3:c.744delA: p.E248fs) but not in another with compound heterozygous missense variants and a slightly divergent clinical profile (NM _000370.3:c.265C>T:p.P89S;c.515C>G:p.T172S). The characteristic magnetic resonance imaging sign of a pallidal T2-weighted hyposignal was observed on reexamination for 1 patient with PLA2G6 mutations (NM_003560.3:c.1903C>T: p.R635X;c.T2411C:p.L804P), allowing us to classify the variants as probably causative. Trait biomarkers, although not obligatory, are invaluable diagnostic tools when present. In the absence of such biomarkers, it is often difficult to reach a definite conclusion, as for the 49 VUS that we identified (eTable 3 in the Supplement).
Limitations
The major limitations of our approach rely in the fact that we missed some variants (ie, trinucleotide repeats expansions that cannot be detected by short-read sequencing and variants in genes not included in our design). The first fallback is inherent to the sequencing technique and can only be avoided by choosing another sequencing approach. The second limitation is a bioinformatics issue that can be solved by updating the gene list. Compared with the panel techniques, the coverage of all human genes might also not be optimized and the sequencing might be more expensive.
Conclusions
We aimed at assessing the efficacy of exome-targeted capture sequencing followed by analysis of genes known to be broadly linked to ataxia to identify mutations in undiagnosed patients. This technique is not optimized for sequencing a specific subset of genes, contrary to focused resequencing arrays, but is commonly available and allows the post hoc reanalysis of data as new causative genes are identified and the inclusion of a broader range of genes in the study design. We focused on a set of 209 genes, which allowed 30% of additional diagnoses in our otherwise extensively prescreened cohort. Our results confirm the genetic heterogeneity of CA, with many genes still to discover in ongoing work with this large cohort. Our strategy may be efficacious for obtaining results for known genes and for future development. 
